Treats HPV-positive atypical cervical cells found on screening
Part of Cancer, Women’s health & pregnancy clinical trials.
This study is for women whose cervical screening shows atypical glandular cells and who test positive for HPV types 16 or 18. It aims to decide the best way to triage and manage these findings so people get the right follow-up and treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can understand the study and sign a consent form.
- Your cervical screening test showed atypical glandular cells (AGC).
- You tested positive for HPV type 16 or HPV type 18.
- Your HPV test must not be negative.
- Your results must include HPV 16 and/or HPV 18 (not just other HPV types).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether removing a small piece of the cervix (cone biopsy) can help diagnose hidden precancer when regular tests are unclear. It may help you get a clearer diagnosis if you have ongoing HPV or abnormal cell changes.
This trial studies a “conservative” (less immediate) approach to a specific abnormal cervix finding to see if it can be managed safely for people who want future pregnancies. It uses close follow-up visits instead of immediate procedures for certain results.
This trial checks whether “therapy abstention” (not treating right away) and close monitoring is safe for certain high-grade cervical cell changes. It may help some people avoid immediate procedures while still catching any progression early.
This study tests an experimental vaccine (RG002) for women with cervical pre-cancer caused by HPV types 16 or 18. The vaccine is designed to help the body fight the virus and potentially clear the pre-cancerous cells, possibly avoiding more invasive treatments.
This study looks at better ways to manage early precancerous changes in the cervix (called high-grade lesions) without surgery. It aims to find which approaches work best for women who have not been vaccinated against HPV.
This early (Phase 1) study tests a new treatment for people with long-lasting mild abnormal Pap test results (ASC-US or LSIL) who also have HPV16 found on testing. It aims to find out whether the treatment can be given safely and may affect the HPV and abnormal cell changes.
Hear when a new Uterine Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.